ReviewBiomedicines2023
Helminth Lessons in Inflammatory Bowel Diseases (IBD).
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- The TPx Protein ofCells · 2026Article
- Immune protection mediated by Echinococcus granulosus EgM123 in the dextran sodium Sulfate-induced colitis model in mice.Molecular biology reports · 2026Article
- Helminth exposure influences Th17 plasticity, suppressing inflammatory and promoting regulatory activity by Th17 lineage cells.Frontiers in immunology · 2026Article
- Effect of Nematodes-Bacteria Complex Metabolites on Cancer and Tumor Progression.Biomolecules · 2025Review
- Coevolutionary interplay: Helminths-trained immunity and its impact on the rise of inflammatory diseases.eLife · 2025Review
- Helminth Seropositivity Inversely Correlated with Th1 and Th17 Cytokines and Severe COVID-19.Vaccines · 2025Article
- Human Umbilical Cord Mesenchymal Stem Cell-derived Exosome Regulates Intestinal Type 2 Immunity.Current stem cell research & therapy · 2025Article
- Helminth-induced immune modulation in colorectal cancer: exploring therapeutic applications.Frontiers in immunology · 2025Review
- Hymenolepis nana antigens alleviate ulcerative colitis by promoting intestinal stem cell proliferation and differentiation via AhR/IL-22 signaling pathway.PLoS neglected tropical diseases · 2024Article
- Pharmaceutical Potential of Remedial Plants and Helminths for Treating Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases.Biomedicines · 2023Article
- Inflammatory cell responses in biliary mucosa duringOpen veterinary journal · 2023Article
- Editorial: Parasitism: the good, the bad and the ugly.Frontiers in veterinary science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Helminths are multicellular invertebrates that colonize the gut of many vertebrate animals including humans. This colonization can result in pathology, which requires treatment. It can also lead to a commensal and possibly even a symbiotic relationship where the helminth and the host benefit from each other's presence. Epidemiological data have linked helminth exposure to protection from immune disorders that include a wide range of diseases, such as allergies, autoimmune illnesses, and idiopathic inflammatory disorders of the gut, which are grouped as inflammatory bowel diseases (IBD). Treatment of moderate to severe IBD involves the use of immune modulators and biologics, which can cause life-threatening complications. In this setting, their safety profile makes helminths or helminth products attractive as novel therapeutic approaches to treat IBD or other immune disorders. Helminths stimulate T helper-2 (Th2) and immune regulatory pathways, which are targeted in IBD treatment. Epidemiological explorations, basic science studies, and clinical research on helminths can lead to the development of safe, potent, and novel therapeutic approaches to prevent or treat IBD in addition to other immune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.